Prostate cancer Prostate cancer
Conditions
Interventions
Myriad MyChoice®-test
Sponsors
Myriad Genetic Laboratories, Inc.
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Participant must be male and = 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place), at the time of signing the ICF. • Participant must have a histologically documented diagnosis of prostate adenocarcinoma. Participants with pathologic features of small cell, neuroendocrine, sarcomatoid, spindle cell, or signet cell histology are not eligible.
Exclusion criteria
Exclusion criteria: • Tumour tissue taken from a previously irradiated lesion. • Fresh (non-FFPE) tissue • Fine-needle aspirates or other cytologies • Do not ‘bake’ or expose the sample to heat during the drying process of freshly prepared tissues sections as this will reduce tissue recovery and lead to lower DNA extraction yields. • Use of other fixatives (e.g. Bouins, B5, Holland’s, zinc buffered formalin), only samples fixed with neutral buffered formalin are accepted for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study wants to confirm if the MyChoice assay can reliably identify which patients will benefit from treatment with saruparib. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. | — |
Countries
Argentina, Australia, Austria, Belgium, Brazil, Canada, Finland, France, Germany, Hungary, India, Israel, Italy, Japan, Netherlands, Peru, Poland, South Korea, Spain, Sweden, Taiwan, Thailand, Turkey, United Kingdom, United States
Contacts
Public ContactRH Henderson
Myriad Genetic Laboratories, Inc.
Outcome results
None listed